We think you have liked this presentation. If you wish to download it, please recommend it to your friends in any social system. Share buttons are a little bit lower. Thank you!
Presentation is loading. Please wait.
Published byKai Wilemon
Modified about 1 year ago
AnCompany.... Monitoring New Drugs for Safety in Insurance Claims Alexander M. Walker Sr VP Epidemiology I3 Magnifi
Monitoring New Drugs Copyright © 2005 i3page 1 The Need A routine, comprehensive system “All” drugs, “all” outcomes Capable of generating signals –Verified elsewhere –Tested internally Capable of testing signals from other sources Serving all stakeholders –Patients –Doctors –Payers –Managed care –Regulators –Manufacturers
Monitoring New Drugs Copyright © 2005 i3page 2 An i3 Response to the Need An active drug safety surveillance program Using the full data assets of United Health Group concerning 11 million individuals Pushing closer and closer to “real time” surveillance
Monitoring New Drugs Copyright © 2005 i3page 3 Technical Number of drugs ~20 NMEs introduced each year Bring into follow when there is a critical number of users Data source ~11 million individuals, open formulary Growing constantly: Oxford, MAMSI, Americhoice,.. Data quality These are insurance claims data, no better no worse Significant in-house experience in sorting, cleaning, extracting medical data from these Reflects real-life drug use
Monitoring New Drugs Copyright © 2005 i3page 4 Three Filters for Effective Claims- Based Surveillance Treatment-emergent diagnoses Events associated with diagnoses not seen prior to drug initiations Filters out: continuation of disease Comparator groups Stat methods now exist for identifying comparison groups with similar distributions on demographics, diagnoses, drug use, and health services. Focus on drug-comparator differences. Filters out: “confounding by indication,” concomitant illnesses and their consequences Data mining Look for population and subgroups, as well as outcome combinations that may not be apparent in the crude tables Filters out: deception by the typical result
Monitoring New Drugs Copyright © 2005 i3page 5 Trade-offs in Filtering Advantage Systematic removal of confounding, background noise, and the dominance of the whole reduces false positives Differences that emerge have greater scientific and rhetorical power Disadvantage Loss of ability to detect AE’s that are caught in the filter
Monitoring New Drugs Copyright © 2005 i3page 6 Treatment-emergent diagnoses Identify only Hospitalizations, MD visits, other services Occurring after dispensing Not sharing 1 st 3 digits of ICD with any service in the 6 months preceding 1 st dispensing Removes Progression of disease Concomitant illnesses
Monitoring New Drugs Copyright © 2005 i3page 7 Comparator drug Problem: False positives and noise Not all new Dx’s are drug AEs – “natural history” / background incidence Claims far from perfect Response: Similar drug, similar people for comparison Choose a standard drug (usually the most prescribed for same indication) Choose users of that drug who resemble the users of Registry Drug with respect to medical history, drugs, doctors, procedures, health services utilization Statistically balanced for all elements available from claims
Monitoring New Drugs Copyright © 2005 i3page 8 Treated Group Control Group P Drug Launch Time Follow-Up Treated Group Control Group P Follow-Up Treated Group Control Group P Follow-Up Treated Group Control Group P Follow-Up Outcome Follow-up conducted in all sets of matched cohorts Dynamic comparator matching
Monitoring New Drugs Copyright © 2005 i3page 9 Data mining Good comparisons, good data still not enough –Drug/comparator tables can still obscure important relations –So many outcomes to look at Evaluate clinically meaningful subsets Search for hidden multi-way associations
Monitoring New Drugs Copyright © 2005 i3page 10 The program Quarterly reports on all New Molecular Entities Treatment patterns New Diagnoses Emerging During Treatment Data-mining Interactive query Data feed Annual print and web-based summaries
Monitoring New Drugs Copyright © 2005 i3page 11 Timeline Beta-version of four drugs available end of August –NMEComparator –Cialis Viagra –CymbaltaEffexor –SpirivaAtrovent –KetekBiaxin All NMEs with >1000 users since 2004 by end of 2005
What Is the Role for Analyses of Administrative Data in Assessing Drug Safety in Post-Market Commitment (PMC) Studies? Cathy W. Critchlow, PhD Global Epidemiology,
Study Design Considerations for Observational Comparative Effectiveness Research Prepared for: Agency for Healthcare Research and Quality (AHRQ)
Comparison of ONC & LTPAC EHR Functional Criteria AND Testimony to HITPC C/A Workgroup (Summary & Detail Slides) January 10, 2014 (Updated 1/17/2014) Jennie.
Evaluating health informatics projects Reasons for and problems of evaluation Objective model Subjective model.
Bias in Clinical Trials. Bias Having a preference to one particular person / group / point of view - “one-sided inclination” Prejudice – negative.
2009 HIMSS Analytics Mapping EMRAM and the Ambulatory EMR Adoption Model to Meaningful Use Criteria September 9, 2009 Mike Davis.
Donald T. Simeon Caribbean Health Research Council.
Delivery System Design presenter location Event (LS#1 or an introduction)
A Model for Program Planning in Health Promotion PRECEDE - PROCEED.
Biometrics India, Pfizer Global R & D The Concept of Randomization and Blinding in Clinical Trials Suraj P Anand.
Thoughts on the Use of Decision Analysis in the Review of New Drug Applications October 3, 2007 Todd Durham.
Patient Centered Medical Home Data and Recognition Review for Saint Lukes Medical Group by Jennifer Woods, RN, BSN Director of Physician Practice Management.
How to design a statistical study How to collect data by doing an observational study, performing an experiment, using a simulation, or using a survey.
The Patient-Centered Medical Home (PCMH): Building a Better Health Care Model.
© 2010 IBM Corporation Lets Build A Smarter Planet: Healthcare Dr. Ulrich Pluta - IBM Global Healthcare.
Thomas Songer, PhD Introduction to Research Methods In the Internet Era Epidemiology as a Population Science Basic Epidemiology Measures Introduction to.
Linda Kenney, MPH November 6, MATERNAL & CHILD HEALTH SERVICES BLOCK GRANT PROGRAM GENERAL INTRODUCTION REQUIREMENTS 2.
Primary and secondary use of EHR: Enhancing clinical research Pharmaceutical Industry Perspectives Dr. Karin Heidenreich Senior Public Affairs Manager/Novartis.
1 Skilling Up for Patient-Centered E-Health E. Vance Wilson University of Wisconsin-Milwaukee.
World Bank Training Program on HIV/AIDS Drugs Training Module 5 Procurement based on the World Bank document Battling HIV/AIDS: A Decision Makers Guide.
Evidence Based Medicine DARWIN AMIR Bgn Penyakit Saraf RS DR. M. Djamil / Fakultas Kedokteran Universitas Andalas PADANG.
Masterclass: Tertiary entrance and senior data interpretation Glen Whitaker, Acting Assistant Director, Analysis and Reporting Branch.
Regulatory Clinical Trials Clinical Trials. Clinical Trials Definition: research studies to find ways to improve health Definition: research studies to.
Randomized controlled trials Hilde Kløvstad Tallin, 6 September 2005.
Medication safety Good Hospital Practice Objectives of this presentation To highlight the importance of ensuring the safe use of medications in.
Health Care Reform and the New MTM Provisions: What does this Mean for Community Pharmacy? Christopher R. Gauthier, RPh Board Coordinator Maine Pharmacy.
Introduction to Patient Safety Research Presentation 9 - Understanding Causes: Cohort Study.
Effectiveness of screening for GBV Effectiveness of screening for GBV Claudia Garcia-Moreno World Health Organization Integrating Gender-based violence.
FUTURE OF HEALTH CARE WORKGROUP TEXAS HEALTH INSTITUTE AUSTIN, TEXAS Thursday, May 10, 2012.
POSTER TEMPLATE BY: University of North Carolina Wilmington A Novel Collaborative Practice Model (CPM) for the Treatment of.
© 2016 SlidePlayer.com Inc. All rights reserved.